The BIO Investor Forum is the premier event for emerging private and public companies to connect with prospective investors to make the deals that drive our industry. More than 220 investors are already registeredfor this year, with one month to go.
The foundation for the success of an event of such magnitude as BIO Investor Forum rests on three main pillars: the educational program, registered companies/presentations, and qualified investor attendees. We at BIO set out to recruit more than 170 of the hottest start-ups and emerging companies to present. We get the pulse on the latest life science investment trends from sophisticated investment and company executives, along with active early-stage investors who can evaluate fresh investment opportunities including compatible, complementary and competitive companies while benefiting from a dozen candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
BIO makes it a point to meticulously review the qualifications of each company and investor in order to ensure the high-quality of interactions that occur at our events between corporate and investor colleagues and during investor/company one-on-one meetings.
This year’s event is attracting investors from over 40 funds with more than $1B assets under management such as ARCH Ventures Partners, Canaan Partners, Longitude Capital, and NEA; over 120 funds specializing in Angel/Series A placements such as 5AM Ventures, Astellas, and Remiges Ventures; and over 20 funds from outside the U.S. including Medivate Partners, Sofinnova, and Taiho Ventures. In just two days at the BIO Investor Forum, you could meet with the potential partners it would take you weeks to visit otherwise…